Stay updated with breaking news from Steven Shallcross. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Theriva Biologics (TOVX) announced the FDA has granted Fast Track Designation to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma.
Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc.
Operator: Ladies and gentlemen, good morning, and welcome to the Theriva Biologics, Inc. 2023 Second Quarter Earnings Conference Call.
Theriva Biologics (NYSE:NYSE:TOVX) Q3 2022 Earnings Conference Call November 10, 2022 08:30 ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive...
FORT PIERCE, FL / ACCESSWIRE / July 7, 2022 / Twin Vee PowerCats Co. (Nasdaq:VEEE) ("Twin Vee" or the "Company"), a designer, manufacturer, distributor, and marketer of power sport catamaran boats, today